Literature DB >> 19594747

Detection of gene copy number aberrations in mantle cell lymphoma by a single quantitative multiplex PCR assay: clinicopathological relevance and prognosis value.

Fabrice Jardin1, Jean-Michel Picquenot, Françoise Parmentier, Philippe Ruminy, Marie Cornic, Dominique Penther, Philippe Bertrand, Hélène Lanic, Ophélie Cassuto, Catherine Humbrecht, Emilie Lemasle, Agathe Wautier, Christian Bastard, Hervé Tilly.   

Abstract

The t(11;14)(q13;q32) is the hallmark of mantle cell lymphoma (MCL). Additional genetic alterations occur in the majority of cases. This study aimed to design a polymerase chain reaction (PCR) assay to determine the incidence and relevance of recurrent gene copy number aberrations in this disease. Forty-two MCL cases with frozen- or paraffin-embedded (FFPE) tissues were selected. Three different quantitative Multiplex PCR of Short Fluorescent Fragments (QMPSF) assays were designed to simultaneously analyse eight genes (CDKN2A, RB1, ATM, CDK2, TP53, MYC, CDKN1B, MDM2), to analyse the 9p21 locus (CDKN2A/CDKN2B) and FFPE tissues. Gains of MYC, CDK2, CDKN1B, and MDM2 were observed in 10% of cases. Losses of RB1, CDKN2A, ATM or TP53 were observed in 38%, 31%, 24% and 10% of cases, respectively. Analysis of the 9p21 locus indicated that, in most cases, tumours displayed a complete inactivation of p14(ARF)/p15I(NK4B)/p16I(NK4A). CDKN2A and MYC aberrations were associated with a high MCL international prognostic index (MIPI). CDK2/MDM2 gains and CDKN2A/TP53 losses correlated with an unfavourable outcome. PCR experiments with frozen and FFPE-tissues indicated that our approach is valid in a routine diagnostic setting, providing a powerful tool that could be used for patient stratification in combination with MIPI in future clinical trials.

Entities:  

Mesh:

Year:  2009        PMID: 19594747     DOI: 10.1111/j.1365-2141.2009.07791.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

Review 1.  Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma.

Authors:  Adalgisa Condoluci; Davide Rossi; Emanuele Zucca; Franco Cavalli
Journal:  Curr Oncol Rep       Date:  2018-08-22       Impact factor: 5.075

2.  High resolution array comparative genomic hybridization identifies copy number alterations in diffuse large B-cell lymphoma that predict response to immuno-chemotherapy.

Authors:  F Kreisel; S Kulkarni; R T Kerns; A Hassan; H Deshmukh; R Nagarajan; J L Frater; A Cashen
Journal:  Cancer Genet       Date:  2011-03

Review 3.  Double-hit mantle cell lymphoma with MYC gene rearrangement or amplification: a report of four cases and review of the literature.

Authors:  Reza Setoodeh; Stuart Schwartz; Peter Papenhausen; Ling Zhang; Elizabeth M Sagatys; Lynn C Moscinski; Haipeng Shao
Journal:  Int J Clin Exp Pathol       Date:  2013-01-15

4.  Copy-neutral loss of heterozygosity and chromosome gains and losses are frequent in gastrointestinal stromal tumors.

Authors:  Nelson Lourenço; Zofia Hélias-Rodzewicz; Jean-Baptiste Bachet; Sabrina Brahimi-Adouane; Fabrice Jardin; Jeanne Tran van Nhieu; Frédérique Peschaud; Emmanuel Martin; Alain Beauchet; Frédéric Chibon; Jean-François Emile
Journal:  Mol Cancer       Date:  2014-11-06       Impact factor: 27.401

5.  Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells.

Authors:  Simon Body; Anna Esteve-Arenys; Hadjer Miloudi; Clara Recasens-Zorzo; Guergana Tchakarska; Alexandra Moros; Sophie Bustany; Anna Vidal-Crespo; Vanina Rodriguez; Régis Lavigne; Emmanuelle Com; Isolda Casanova; Ramón Mangues; Oliver Weigert; Alejandra Sanjuan-Pla; Pablo Menéndez; Bénédicte Marcq; Jean-Michel Picquenot; Patricia Pérez-Galán; Fabrice Jardin; Gaël Roué; Brigitte Sola
Journal:  Sci Rep       Date:  2017-10-24       Impact factor: 4.379

Review 6.  Management of Drug Resistance in Mantle Cell Lymphoma.

Authors:  Gaël Roué; Brigitte Sola
Journal:  Cancers (Basel)       Date:  2020-06-12       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.